Dana dhuwit perusahaan uniqure.com (QURE)

uniQure N.V. is a leader in commercial gene therapy with robust patent protection and licensing revenues. The current cash balance demonstrates liquidity dynamics, where 0.66 is recorded as the baseline value. However, cash flows remain volatile due to one-time partner payments, although strong management with its own manufacturing base ensures a high level of credibility.
uniQure (QURE) - rincian metrik lan laporan keuangan

This indicator aggregates the balance sheet's liquid assets, measuring the volume of available capital to cover operating expenses and protect against cash flow gaps. For uniQure N.V. (QURE), this reserve is critically important when combining in-house production with the delegation of late-stage trials to external CROs, which is confirmed by the company's cash history as a tool for managing financial autonomy.